Revelation Biosciences, INC

Revelation Biosciences, Inc. has adopted a stockholder rights plan and declared a dividend of one preferred share purchase right for each outstanding common share.

Revelation Biosciences updates executive agreements, amends bylaws, and reports annual meeting voting results.

Revelation Biosciences, Inc. has published an updated corporate presentation detailing its current strategic initiatives.

Revelation Biosciences announced its first-quarter 2026 financial results, highlighting progress in its Gemini development program and a strengthened cash position.

Revelation Biosciences, Inc. stockholders approved the issuance of common stock related to Class J Warrants, allowing the company to exceed Nasdaq's 20% Exchange Cap.

Revelation Biosciences, Inc. announced its financial results for the three and twelve months ended December 31, 2025, highlighting positive clinical study results for its Gemini program.

Revelation Biosciences reported increased operating expenses and net losses for the six months ended June 30, 2026, raising substantial doubt about its ability to continue as a going concern and facing potential Nasdaq delisting.

Revelation Biosciences reports a reduced net loss and increased cash, but raises substantial doubt about its ability to continue as a going concern without further capital raises.

Revelation Biosciences reports a net loss of $4.5M for Q2 2025, highlighting ongoing challenges in funding and development.

Revelation Biosciences reports a net loss of $2.1 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.

Revelation Biosciences reported a net loss of $2.2 million for Q3 2024 and is addressing Nasdaq listing compliance issues.

Revelation Biosciences has filed an amendment to its original quarterly report to include previously omitted language in its certifications.

Revelation Biosciences, a clinical-stage biotech, reported recurring losses and a going concern qualification, despite advancing its kidney disease drug candidates and recent capital raises.

Revelation Biosciences, a clinical-stage life science company, announces its 2024 financial results and the start of a Phase 1b clinical study for Gemini-CKD in chronic kidney disease patients.

Revelation Biosciences has filed an amendment to its annual report to correct an omission in the certifications of its principal executive and financial officers.

Revelation Biosciences' 10-K filing details its focus on developing innate immune system therapeutics, including programs for surgical site infections, acute kidney injury, and chronic kidney disease.

James Rolke, Chief Executive Officer and a Director of Revelation Biosciences, Inc., received 208,076 shares of common stock on August 17, 2026.

Lakhmir S Chawla, a Director of Revelation Biosciences, Inc., received 32,011 shares of common stock on August 17, 2026.

Chester Stanley Zygmont Iii, Chief Financial Officer of Revelation Biosciences, Inc., reported multiple transactions in common stock on August 17, 2026.

Jess Roper, a Director of Revelation Biosciences, Inc., received 32,011 shares of common stock on August 17, 2026.

Jennifer Carver, a Director of Revelation Biosciences, Inc., received 32,011 shares of common stock on August 17, 2026.

Revelation Biosciences CEO James Rolke sold 10,115 shares to cover mandatory tax withholding obligations related to restricted stock vesting.

Revelation Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 24, 2026, and is seeking stockholder approval for a reverse stock split to maintain Nasdaq listing compliance.

Revelation Biosciences, Inc. is holding a Special Meeting to seek stockholder approval for the issuance of common stock related to recent Class J Warrants, crucial for funding its lead product candidate, Gemini.

Revelation Biosciences, Inc. calls a Special Meeting to approve the issuance of common stock exceeding Nasdaq's 20% cap, crucial for funding and continued listing.

Revelation Biosciences, Inc. calls a Special Meeting to approve the issuance of common stock exceeding Nasdaq's 20% cap, crucial for funding operations and maintaining listing.

Revelation Biosciences, Inc. has announced its 2025 Annual Meeting of Stockholders, where key proposals include a potential reverse stock split, an amendment to its equity incentive plan, and approval for share issuance related to recent warrants, all while acknowledging substantial doubt about its ability to continue as a going concern.

Revelation Biosciences is reminding shareholders to vote in favor of Proposal 2 at the upcoming special meeting on January 17, 2025, which aims to redomicile the company to Nevada and save at least $200,000 annually in franchise tax fees.

Revelation Biosciences launches a best efforts public offering aiming to raise up to $5 million through shares, pre-funded warrants, and common stock warrants.

Revelation Biosciences files for a best efforts public offering to raise capital for its Gemini-based programs targeting acute kidney injury, chronic kidney disease, and post-surgical infections.

Revelation Biosciences files an amendment to its S-1 registration statement for a proposed public offering of common stock and warrants.

Revelation Biosciences plans a best efforts public offering of common stock, pre-funded warrants, and Class D Common Stock Warrants to raise capital for clinical development and general corporate purposes.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 4.99% of Revelation Biosciences, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 323,241 shares, representing 7.80% of the outstanding common stock of Revelation Biosciences, Inc.

Sabby Management, Hal Mintz, and Sabby Volatility Warrant Master Fund have collectively reported a 9.6% beneficial ownership stake in Revelation Biosciences, Inc.

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Revelation Biosciences, Inc., holding 250,755 shares of common stock.

Sabby Management, LLC, Sabby Volatility Warrant Master Fund Ltd, and Hal Mintz have reported a passive beneficial ownership of 4.9% in Revelation Biosciences, Inc. common stock.